I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1450, bn the date-shown below.

Docket No.: COTH-P02-001 (PATENT)

Dated: \_\_\_\_\_\_ Signature: \_\_\_\_\_(Susan La

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Afeyan et al.

Application No.: 10/650591

Confirmation No.: 7918

Filed: August 27, 2003

Art Unit: 1652

For: ADZYMES AND USES THEREOF

Examiner: Saidha, Tekchand

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. §1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached with the exception of the U.S. patents.

Applicants also enclose a copy of the argument by Richard Wagner that accompanied the untimely filed Protest under 37 C.F.R. §1.291. This document is provided merely in an excess of caution to ensure compliance with the disclosure requirement under Rule 56. Applicants have not yet determined whether or not these arguments are material to the instant application, and no

Application No.: 10/650591 Docket No.: COTH-P02-001

conclusion regarding materiality should be drawn from the inclusion of these documents in this Supplemental Information Disclosure Statement.

In accordance with 37 C.F.R. §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. COTH-P02-001. A duplicate copy of this paper is enclosed.

Dated: July 1, 2005

Respectfully submitted,

Yu Lu, Ph.D.

Registration No.: 50,306 ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

### PTO-1449 REPRODUCED

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

May 31, 2005 (Use several sheets if necessary)

	· · · · · · · · · · · · · · · · · · ·		
ATTORNEY DOCKET NO.	PLICATION NO. 10/650,591		
FIRST NAMED APPLICANT Afeyan, Noubar B., et al.			
FILING DATE August 27, 2003	confirmation no. 7918	GROUP 1652	

	U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	MM-DD-YYYY ISSUE DATE / PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT  Bristol-Myers Company		
	AA	4,975,278	12-04-1990			
	Α̈́B	5,258,498	11-02-1993	Huston et al.		
	AC	5,961,973	10-05-1999	Crea		
	AD	5,811,265	09-22-1998	Quertermous et al.		
		;				

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	MM-DD-YYYY PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO		
AL	WO 00/64485 A2	11-02-2000	Genencor International, Inc.			
	AL		FOREIGN PATENT DO  MM-DD-YYYY  DOCUMENT NUMBER PUBLICATION DATE	FOREIGN PATENT DOCUMENTS  MM-DD-YYYY DOCUMENT NUMBER  MM-DD-YYYY PUBLICATION DATE  NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR	Holvoet, Paul, et al., "Characterization of a Chimeric Plasminogen Activator Consisting of a Single-chain Fv Fragment Derived from a Fibrin Fragment D-Dimer-specific Antibody and a Truncated Single-chain Urokinase," J. Biological Chemistry, 266(29): 19717-19724 (1991).				
AS	Collen, Desire and Lijnen, H. Roger, "New thrombolytic agents and strategies," Baillière's Clinical Haematology, 8(2): 425-435 (1995).				

		<del></del>
EXAMINER	DATE CONSIDERED	** *
	J J	
1		·
li .	1	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 1 of

Complete if Known				
Application Number	10/650591			
Filing Date	August 27, 2003			
First Named Inventor	Noubar B. Afeyan			
Art Unit	1652			
Examiner Name	Saidha, Tekchand			
Attorney Docket Number	COTH-P02-001			

U.S. PATENT DOCUMENTS						
Examiner Cite Document Number Publication Date Name of Patentee or Relevant Passages or Relevant						
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	AG	US-4,975,278	12-04-1990	Senter et al.		
	AH	US-5,258,498	11-02-1993	Huston et al.		
	ΑĪ	US-5,811,265	09-22-1998	Quertermous et al.		
	AJ	US-5,961,973	10-05-1999	Crea		

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
BF WO 00/64485-A2		11-02-2000	Genencor International, Inc.			
	et al.					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	СТ	COLLEN, D., et al., "New thrombolytic agents and strategies," Bailliere's Clinical Haematology, 8(2):425-435 (1995).			
	CU	HOLVOET, P., et al., "Characterization of a Chimeric Plasminogen Activator Consisting of a Single-chain Fv Fragment Derived from a Fibrin Fragment D-Dimer-specific Antibody and a Truncated Single-chain Urokinase," The Journal of Biological Chemistry, 266(29):19717-19724 (1991).			
	CV	WAGNER, R., Copy of Untimely Filed Protest under 37 C.F.R. § 1.291.			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner	D	ate	
Signature	C	considered	

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/650591

Attorney Docket No.: COTH-P02-001

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

On July 1, 2005

Date

Signature

Susan Lanney

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (7 References) (1 page)
Supplemental Information Disclosure Statement (2 Pages)
7 Cited References (AG-AJ, BF, CT-CU)
Copy of Untimely Filed Protest under 37 C.F.R. § 1.291. (CV)
This return receipt postcard